SCRIBE
The Single-Case Reporting guideline In BEhavioural interventions (SCRIBE) - Lista de verificação
Esta é uma lista de 26 itens que devem ser incluídos nos relatórios de investigação de desenhos de caso único (ou desenhos semelhantes com muito poucos participantes).
Antes de submeterem o seu manuscrito, os/as autores/as devem utilizar esta lista de verificação para garantir que incluem todas as informações necessárias. Recomenda-se que cada critério seja cuidadosamente revisto e que se anote em que página do manuscrito é relatado (ou se não se aplica à investigação que está a ser submetida).
Desenvolvido a partir de: Robyn L. Tate, et al. (2016). The Single-Case Reporting guideline In BEhavioural interventions (SCRIBE) 2016 statement. Journal of School Psychology, 56, 133-142. https://doi.org/10.1016/j.jsp.2016.04.001
Item number |
Topic |
Item description |
Reported |
TITLE and ABSTRACT |
|||
1 |
Title |
Identify the research as a single-case experimental design in the title |
|
2 |
Credentials |
Summarize the research question, populalion, design, methods including in!ervention/s (independent variable/s) and target behavior/s and any other outcome/s (dependent variable/s), results, and conclusions |
|
INTRODUCTION |
|||
3 |
Scientific background |
Describe the scientific background to identify issue/s under analysis, current scientific knowledge, and gaps in that knowledge base |
|
4 |
Aims |
State the purpose/aims of the study, research question/s, and, if applicable, hypotheses |
|
METHOD |
|||
|
|||
5 |
Design |
ldemify the design (e.g., withdrawal/reversal, multiple-baseline, alternating-treatments, changing-criterion, some combination thereof, or adaptive design) and describe the phases and phase sequence (whether determined a priori or data-driven) and, if applicable, criteria for phase change |
|
6 |
Procedural changes |
Describe any procedural changes that occurred during the course of the investigation after the start of the study |
|
7 |
Replication |
Describe any planned replication |
|
8 |
Randomization |
State whether randomization was used, and if so, describe the randomization method and the elements of the study that were randomized |
|
9 |
Blinding |
State whether blinding/masking was used, and if so, describe who was blinded/masked |
|
|
|||
10 |
Selection criteria |
State the inclusion and exclusion criteria, if applicable, and the method of recruitment |
|
11 |
Participant characteristics |
For each participant, describe the demographic characteristics and clinical (or other) features relevant to the research question, such that anonymity is ensured |
|
|
|||
12 |
Setting |
Describe characteristics of the setting and location where the study was conducted |
|
|
|||
13 |
Ethics |
State whether ethics approval was obtained and indicate if and how informed consent and/or assent were obtained |
|
|
|||
14 |
Measures |
Operationally define all target behaviors and outcome measures, describe reliability and validity, state how they were selected, and how and when they were measured |
|
15 |
Equipment |
Clearly describe any equipment and/or materials (e.g., technological aids, biofeedback, computer programs, intervention manuals or other material resources) used to measure target behavior/s and other outcome/s or deliver the interventions |
|
|
|||
16 |
Intervention |
Describe the intervention and control condition in each phase, including how and when they were actually administered, with as much detail as possible to facilitate attempts at replication |
|
17 |
Procedural fidelity |
Describe how procedural fidelity was evaluated in each phase |
|
|
|||
18 |
Analyses |
Describe and justify all methods used to analyze data |
|
RESULTS |
|||
19 |
Sequence completed |
For each participant, report the sequence actually completed, including the number of trials for each session for each case. For participant/s who did not complete, state when they stopped and the reasons |
|
20 |
Outcomes and estimation |
For each participant, report results, including raw data, for each target behavior and other outcome/s |
|
21 |
Adverse events |
State whether or not any adverse events occurred for any participant and the phase in which they occurred |
|
DISCUSSION |
|||
22 |
Interpretation |
Summarize findings and interpret the results in the context of current evidence |
|
23 |
Limitations |
Discuss limitations, addressing sources of potential bias and imprecision |
|
24 |
Applicability |
Discuss applicability and implications of the study findings |
|
DOCUMENTATION |
|||
25 |
Protocol |
If available, state where a study protocol can be accessed |
|
26 |
Funding |
Identify source/s of funding and other support; describe the role of funders |